Free Trial
→ Expert Alert: Massive Bubble Could Crash Your Wealth (From American Alternative) (Ad)tc pixel

RTW Biotech Opportunities (LON:RTW) Stock Price Down 0.7% - Here's What Happened

Written by MarketBeat
Updated August 26, 2025
RTW Biotech Opportunities logo with Financial Services background

Key Points

  • RTW Biotech Opportunities (LON:RTW) saw a 0.7% decline in its stock price during mid-day trading, closing at GBX 1.40 ($0.02) with a substantial drop in trading volume.
  • The company has a market capitalization of £470.28 million and a PE ratio of 3.34, indicating a low relative valuation in the market.
  • RTW focuses on investing in transformative biopharmaceutical and medical technology assets, aiming to support innovative companies developing advanced therapies.
  • Five stocks to consider instead of RTW Biotech Opportunities.

RTW Biotech Opportunities (LON:RTW - Get Free Report)'s stock price dropped 0.7% on Wednesday . The company traded as low as GBX 1.40 ($0.02) and last traded at GBX 1.40 ($0.02). Approximately 21,838 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 304,133 shares. The stock had previously closed at GBX 1.41 ($0.02).

RTW Biotech Opportunities Price Performance

The stock has a market cap of £470.28 million, a price-to-earnings ratio of 3.34 and a beta of 0.60. The stock's 50 day moving average price is GBX 1.29 and its two-hundred day moving average price is GBX 1.24.

RTW Biotech Opportunities Company Profile

(Get Free Report)

RTW Biotech Opportunities Ltd LSE: RTW is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Bio invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

Featured Stories

Should You Invest $1,000 in RTW Biotech Opportunities Right Now?

Before you consider RTW Biotech Opportunities, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RTW Biotech Opportunities wasn't on the list.

While RTW Biotech Opportunities currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.